There are fears the current insurance industry upheaval will force some biotechs to the wall unless the Gene Technology Act 2000 is overhauled.
CSIRO was well on its way to addressing the raft of serious problems outlined in a confidential internal report, the organisation's chief has claimed.
The cone snail, a marine snail from the Great Barrier Reef, is proving to be a vaulable ally in pain management drug research.
Agenix Limited (ASX: AGH) has announced a 435 per cent increase in after-tax profit to $1.7 million for the six months to December 31, 2001.
BioWest, the first directory for the biotechnology industry in western Sydney, is being launched today by Kim Yeadon, NSW Minister for Western Sydney.
Kinase and blood-clotting disease research group Thrombogenix is within weeks of a name change intended to reflect a broader focus.
Sydney-based company Proteome Systems Limited (PSL) has participated in a new round of capital raising as speculation mounts about the timing of the company's public float.
Two biotech companies, Biota Holdings and Progen Industries, have popped up on the Australian Shareholders Association's 2002 list of 'Poor Performers'.
Cell growth factor company GroPep is expecting to record a profit within six months after finalising its purchase of Biotech Australia Group.
Self-made billionaire and secretive philanthropist Charles Feeney appears to have a soft spot for Queensland's biotechnology sector.
US company Ciphergen Biosystems has signed two joint development agreements that will call on its protein chips to find out why AIDS does not progress in a small percentage of HIV-infected individuals.
In your idle moments, your computer can now join the search for a cure for anthrax.
A $1.6 million research centre in Queensland will put advanced photonics tools like laser tweezers in the hands of life science researchers.
OPTISCAN has banked its first installment from the $AUD19.6 million Pentax endomicroscope deal announced last week.
The London Stock Exchange is spruiking for business from Australian biotech companies who want to transmute their intellectual property into financial capital.